Tag Archives: Brad Loncar

Innovent Biologics epitomizes how China, not Russia, quickly becoming real threat to US biotech supremacy.

The News: China’s Innovent Biologics Inc. has raised $150 million in a Series E crossover round, with Capital Group Private Markets picking up $90 million of the mega-round, according to Endpoints. The… Read more »

ASCO, aka The Oncology Super Bowl for Biotechs, sends stocks in every direction

Steve’s Take: As another jam-packed annual meeting of the American Society of Clinical Oncology in Chicago wrapped up on Tuesday (June 6, 2017), with some 38,000 oncologists gathering together at… Read more »

Trump scorns Pharma, calls for drug pricebidding; stocks swoon on latest pivot, but does the POTUS-elect mean it?

President-elect Donald Trump on Wednesday (January 11, 2017) pledged to change the way the federal government purchases prescription drugs, a striking, largely unforseen warning to the drug industry that he… Read more »